Tags

Type your tag names separated by a space and hit enter

Lower dose diuretic therapy in the treatment of patients with mild to moderate hypertension.
J Hum Hypertens. 1994 Aug; 8(8):571-5.JH

Abstract

Indapamide (Lozol), an indoline antihypertensive drug with diuretic and vasodilating activities, was evaluated in 195 patients with mild to moderate essential hypertension (sitting DBP between 95 and 110 mmHg) in a multicentre, randomised, double-blind, parallel-group design trial. A four week single-blind placebo wash-out period was followed by an eight week double-blind period. Patients were randomised to indapamide 1.25 mg/day or to placebo. The primary efficacy endpoint was the mean change in sitting DBP from baseline to week 8. Ninety patients in the placebo group (93%) and 82 patients (84%) in the indapamide group completed the eight weeks of double-blind therapy. Indapamide produced a mean (SE) decrease in sitting DBP of 7.4 (0.63) mmHg (from 100.1 to 92.8 mmHg) compared with a decrease of 3.6 (0.75) mmHg (from 99.6 to 95.8 mmHg) produced by placebo (p < 0.0001). Indapamide and placebo also produced mean decreases in standing DBP of 6.8 (0.75) and 2.8 (0.77) mmHg, respectively (p = 0.0002), in sitting SBP of 11.1 (1.18) and 3.2 (1.35) mmHg, respectively (p = 0.0001) and in standing SBP of 11.4 (1.29) and 4.0 (1.43) mmHg, respectively (P = 0.0002). Reduction in BP of > or = 10 mmHg or to a DBP of < or = 90 mmHg was more frequent (P = 0.0005) among indapamide (46.6%) compared with placebo (23.7%) treated patients. During the eight week double-blind treatment period, incidence rates for all adverse experiences and for drug-related adverse experiences were similar between the two treatment groups.(

ABSTRACT

TRUNCATED AT 250 WORDS)

Authors+Show Affiliations

Hypertension Research Centre, Emory University School of Medicine, Decatur, GA 30030.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

7990083

Citation

Hall, W D., et al. "Lower Dose Diuretic Therapy in the Treatment of Patients With Mild to Moderate Hypertension." Journal of Human Hypertension, vol. 8, no. 8, 1994, pp. 571-5.
Hall WD, Weber MA, Ferdinand K, et al. Lower dose diuretic therapy in the treatment of patients with mild to moderate hypertension. J Hum Hypertens. 1994;8(8):571-5.
Hall, W. D., Weber, M. A., Ferdinand, K., Flamenbaum, W., Marbury, T., Jain, A. K., Weidler, D., Weiss, R., Herron, J., & Codispoti, J. (1994). Lower dose diuretic therapy in the treatment of patients with mild to moderate hypertension. Journal of Human Hypertension, 8(8), 571-5.
Hall WD, et al. Lower Dose Diuretic Therapy in the Treatment of Patients With Mild to Moderate Hypertension. J Hum Hypertens. 1994;8(8):571-5. PubMed PMID: 7990083.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Lower dose diuretic therapy in the treatment of patients with mild to moderate hypertension. A1 - Hall,W D, AU - Weber,M A, AU - Ferdinand,K, AU - Flamenbaum,W, AU - Marbury,T, AU - Jain,A K, AU - Weidler,D, AU - Weiss,R, AU - Herron,J, AU - Codispoti,J, PY - 1994/8/1/pubmed PY - 1994/8/1/medline PY - 1994/8/1/entrez SP - 571 EP - 5 JF - Journal of human hypertension JO - J Hum Hypertens VL - 8 IS - 8 N2 - Indapamide (Lozol), an indoline antihypertensive drug with diuretic and vasodilating activities, was evaluated in 195 patients with mild to moderate essential hypertension (sitting DBP between 95 and 110 mmHg) in a multicentre, randomised, double-blind, parallel-group design trial. A four week single-blind placebo wash-out period was followed by an eight week double-blind period. Patients were randomised to indapamide 1.25 mg/day or to placebo. The primary efficacy endpoint was the mean change in sitting DBP from baseline to week 8. Ninety patients in the placebo group (93%) and 82 patients (84%) in the indapamide group completed the eight weeks of double-blind therapy. Indapamide produced a mean (SE) decrease in sitting DBP of 7.4 (0.63) mmHg (from 100.1 to 92.8 mmHg) compared with a decrease of 3.6 (0.75) mmHg (from 99.6 to 95.8 mmHg) produced by placebo (p < 0.0001). Indapamide and placebo also produced mean decreases in standing DBP of 6.8 (0.75) and 2.8 (0.77) mmHg, respectively (p = 0.0002), in sitting SBP of 11.1 (1.18) and 3.2 (1.35) mmHg, respectively (p = 0.0001) and in standing SBP of 11.4 (1.29) and 4.0 (1.43) mmHg, respectively (P = 0.0002). Reduction in BP of > or = 10 mmHg or to a DBP of < or = 90 mmHg was more frequent (P = 0.0005) among indapamide (46.6%) compared with placebo (23.7%) treated patients. During the eight week double-blind treatment period, incidence rates for all adverse experiences and for drug-related adverse experiences were similar between the two treatment groups.(ABSTRACT TRUNCATED AT 250 WORDS) SN - 0950-9240 UR - https://www.unboundmedicine.com/medline/citation/7990083/Lower_dose_diuretic_therapy_in_the_treatment_of_patients_with_mild_to_moderate_hypertension. L2 - https://medlineplus.gov/highbloodpressure.html DB - PRIME DP - Unbound Medicine ER -